Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)
Status:
Enrolling by invitation
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the
effect of dapagliflozin add-on intensive lifestyle intervention for remission of type 2
diabetes in obese patients with Type 2 Diabetes Mellitus. The study consists of a 12-months
treatment period (in which they will receive either Dapagliflozin plus intensive lifestyle
intervention or placebo plus intensive lifestyle intervention in addition to the background
therapy), and a 2-month follow-up period after treatment period.